Myriocin is a widely studied SPT inhibitor that irreversibly inhibits SPT expression and reduces ceramide levels, playing an important role in the treatment of diabetes, hepatic steatosis and atherosclerosis 150, 151. This evidence concerns the gene AGXT and fatty liver disease.